Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M198Revenue $M7.0Net Margin (%)-1,201.7Z-Score4.7
Enterprise Value $M134EPS $-4.6Operating Margin %-1,186.1F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-1,201.7Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %0Quick Ratio19.4Cash flow > EarningsY
Price/Sales3.15-y EBITDA Growth Rate %0Current Ratio19.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-66.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-174.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M19.7ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ARGS

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

ARGS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ARGS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Pharmstandard International S.10% Owner 2014-02-12Buy1,275,000$825 view
Underdown Brian J.Director, 10% Owner 2014-02-12Buy40,497$825 view
Cooperatieve AAC LS U.A.10% Owner 2014-02-12Buy36,416$825 view
Birner HubertDirector, 10% Owner 2014-02-12Buy39,873$825 view
van Deventer SanderDirector, 10% Owner 2014-02-12Buy36,416$825 view

Press Releases about ARGS :

    Quarterly/Annual Reports about ARGS:

      News about ARGS:

      Articles On GuruFocus.com
      Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

      More From Other Websites
      9:22 am Argos Therapeutics enters into $25 million venture loan facility led by Horizon Technology... Sep 30 2014
      Argos Therapeutics Enters Into $25 Million Venture Loan Facility Led by Horizon Technology Finance Sep 30 2014
      Argos Therapeutics to Present at the 21st Annual BioCentury NewsMakers Conference Sep 19 2014
      Enrollment in Argos Therapeutics' Pivotal Phase III ADAPT Trial of AGS-003 for Metastatic Renal Cell... Sep 18 2014
      Can the Uptrend Continue for Argos Therapeutics (ARGS)? Sep 08 2014
      Argos Announces Issuance of Arcelis(R) Technology Platform Patent Sep 08 2014
      Argos Therapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference Sep 03 2014
      ARGOS THERAPEUTICS INC Financials Aug 22 2014
      ARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Aug 22 2014
      6 Biotech Stocks to Buy Now With Up to 100% Upside Potential Aug 20 2014
      ARGOS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Aug 14 2014
      ARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 13 2014
      Argos Therapeutics Reports Second Quarter 2014 Financial Results and Operational Highlights Aug 13 2014
      Q2 2014 Argos Therapeutics Inc Earnings Release - After Market Close Aug 13 2014
      Argos Therapeutics to Hold Second Quarter 2014 Financial Results Conference Call on Wednesday,... Aug 06 2014
      Argos Therapeutics presents results from trial of AGS-004 Jul 21 2014
      Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable... Jul 21 2014
      Weekly 3-Year Low Highlights: CLUB, ARGS, ONTX, BOTA Jun 08 2014
      ARGOS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 15 2014
      ARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 13 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK